Abstract: A flavoring sheet with improved physical properties, a smoking article including the same, and methods of producing the flavoring sheet and the smoking article are provided. The flavoring sheet according to some embodiments of the present disclosure may include a hydrocolloid material configured to form a sheet, a flavoring, and a plasticizer. The plasticizer can improve physical properties of the flavoring sheet and thus enhance workability of a process of cutting the flavoring sheet.

Abstract: The present invention relates to a composition for treating inflammatory diseases comprising germanium telluride nanosheets coated with polyvinylpyrrolidone, and the nanosheets have excellent anti-inflammatory and thus are excellent in treating inflammatory bowel disease and psoriasis.

Abstract: The present disclosure relates to a plurality of host materials, organic electroluminescent compounds, and organic electroluminescent devices comprising the same. By comprising specific combinations of compounds according to the present disclosure as the plurality of host materials or by comprising a compound according to the present disclosure, it is possible to provide organic electroluminescent devices having improved lifespan characteristics compared to conventional organic electroluminescent devices.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery and a lithium secondary battery including the same are described herein. Specifically, the non-aqueous electrolyte solution for a lithium secondary battery includes a lithium salt, a first solvent including a non-fluorine-based solvent, a second solvent including a fluorine-based carbonate solvent, and a third solvent including a fluorine-based acetate solvent, wherein the fluorine-based carbonate solvent and the fluorine-based acetate solvent are included in a weight ratio of 1:0.5 to 1:1, and a mixed amount of the fluorine-based carbonate solvent and the fluorine-based acetate solvent may be in a range of 3.0 wt % to 30 wt % based on a total weight of the non-aqueous electrolyte solution for a lithium secondary battery.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A lithium secondary battery includes a negative electrode, a positive electrode positioned opposite to the negative electrode, a separator disposed between the negative electrode and the positive electrode, and a non-aqueous electrolyte, wherein the negative electrode includes a silicon-based active material, the silicon-based active material comprises a compound represented by SiOx, wherein 0?x<2, the non-aqueous electrolyte includes a lithium salt, an organic solvent, and an additive, the additive includes a first additive and a second additive, the first additive includes a coumarin-based compound represented by Formula 1, and the second additive includes at least one of lithium fluoromalonato(difluoro)borate (LiFMDFB), lithium difluoro(oxalato)borate (LiDFOB), lithium difluorophosphate (LiDFP), or lithium difluorobis-(oxalate)phosphate (LiDFOP): wherein R and n are described herein.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery according to the present technology includes: a lithium salt; an organic solvent; and a first additive, and the first additive includes a compound represented by following Chemical formula 1: Herein, R1 is a substituted or unsubstituted unsaturated hydrocarbon group having 2 to 20 carbon atoms, and R2 is one selected from the group consisting of a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms and a substituted or unsubstituted cyclic alkyl group having 3 to 8 carbon atoms.

Abstract: The present disclosure provides a non-aqueous electrolyte including an additive for a non-aqueous electrolyte, which is represented by the following Chemical Formula 1: In Chemical Formula 1, R1 to R5 are each independently any one selected from the group consisting of H, an alkyl group having 1 to 10 carbon atoms, and an alkoxy group having 1 to 10 carbon atoms, and R may be an aliphatic unsaturated hydrocarbon group having 2 to 10 carbon atoms, or —OR? (R? is an aliphatic unsaturated hydrocarbon group having 2 to 10 carbon atoms).

Abstract: An additive, a non-aqueous electrolyte solution including the same, and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, a non-aqueous solvent including a propyl propionate, and a compound represented by Formula 1: wherein, in Formula 1, R1 and R2 are each independently hydrogen or a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms.

Abstract: The present disclosure relates to a non-aqueous electrolyte including an organic solvent, a lithium salt, and a coumarin-based compound represented by the following Chemical Formula 1 and a lithium secondary battery including the non-aqueous electrolyte: in Chemical Formula 1, R is a substituent including one or more elements selected from the group consisting of C, O, N, B, S, P, Si, and F, and n is an integer of 1 to 6.

Abstract: The present disclosure relates to a lithium secondary battery comprising a positive electrode including a positive electrode active material, a negative electrode including a negative electrode active material, and a non-aqueous electrolyte. The non-aqueous electrolyte includes an organic solvent, a lithium salt, a coumarin-based compound represented by [Chemical Formula 1], and a halogen-substituted cyclic carbonate, and the positive electrode active material includes a lithium manganese-rich oxide represented by [Chemical Formula 2].

Abstract: The present disclosure relates to a non-aqueous electrolyte for a lithium secondary battery, including a lithium salt, an organic solvent and a compound represented by Chemical Formula 1; and a lithium secondary battery including the same, wherein R1, R2, L and m are described herein.

Abstract: The present disclosure provides a non-aqueous electrolyte including an additive for a non-aqueous electrolyte, which is represented by the following Chemical Formula 1: In Chemical Formula 1, R1 to R5 are each independently any one selected from the group consisting of H, an alkyl group having 1 to 10 carbon atoms, and an alkoxy group having 1 to 10 carbon atoms, and R may be an aliphatic unsaturated hydrocarbon group having 2 to 10 carbon atoms, or —OR? (R? is an aliphatic unsaturated hydrocarbon group having 2 to 10 carbon atoms).

Abstract: The present invention relates to a chimeric antigen receptor having a ligand specifically targeting an anthrax toxin receptor (ANTXR), and, more specifically, to: a nucleic acid encoding a chimeric antigen receptor comprising ligand PA63 specifically binding to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2); a vector comprising the nucleic acid encoding a chimeric antigen receptor; and a recombinant cell comprising the vector; a pharmaceutical composition for preventing or treating solid cancer, comprising the recombinant cell; and a treatment method.

Abstract: An additive, a non-aqueous electrolyte solution including the same, and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, a non-aqueous solvent including a propyl propionate, and a compound represented by Formula 1: wherein, in Formula 1, R1 and R2 are each independently hydrogen or a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms.

Abstract: A heterodimeric Fc-fused protein and a pharmaceutical composition comprising the heterodimeric Fc-fused protein are disclosed. The heterodimeric Fc-fused protein includes first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to at least one of the N-terminus or the C-terminus of the first Fc region and/or the second Fc region, wherein CH3 domains of the first Fc region and the second Fc region are mutated such that the formation of a heterodimer is promoted. When the heterodimeric Fc-fused protein is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery, and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, a non-aqueous solvent including a carbonate-based solvent and propyl propionate, and a compound represented by Formula 1. In some embodiments, the carbonate-based solvent is ethylene carbonate.

Abstract: An electrolyte for a lithium secondary battery of the present invention may improve high-rate charge and discharge characteristics and high-temperature storage and life characteristics of a lithium secondary battery and may achieve an effect of increasing reversible capacity by simultaneously including lithium bis(fluorosulfonyl)imide (LiFSI) and a second lithium salt, as a lithium salt, while including a second additive as well as a novel borate-based lithium compound, as an additive.

Abstract: The present disclosure relates to a gel polymer electrolyte including an imide salt, and a lithium secondary battery including the same and having a protective film formed on a cathode tab. Disclosed are a gel polymer electrolyte that allows the production of a secondary battery having excellent quality with no corrosion of a cathode, while using, as an electrolyte, an imide-based salt effective for improvement of output quality and high-temperature storability, as well as a secondary battery including the same.

Abstract: Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and/or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity.